TriSalus Life Sciences (TLSI) Non-Current Deffered Revenue (2020 - 2023)

TriSalus Life Sciences has reported Non-Current Deffered Revenue for 4 years, with the latest figure at $8.8 million in Q2 2023.

• For the quarter ending Q2 2023, Non-Current Deffered Revenue changed 0.0% year-over-year to $8.8 million; the trailing twelve-month figure through Jun 2023 stood at $8.8 million (changed 0.0% YoY), and the FY2022 full-year result was $8.8 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue for Q2 2023 stood at $8.8 million, roughly flat from $8.8 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $8.8 million in Q4 2020, with the low at $8.8 million in Q4 2020.
• Historically, Non-Current Deffered Revenue has averaged $8.8 million across 4 years, with a median of $8.8 million in 2020.
• The largest YoY upside for Non-Current Deffered Revenue was 0.0% in 2021 against a maximum downside of 0.0% in 2021.
• TriSalus Life Sciences' Non-Current Deffered Revenue stood at $8.8 million in 2020, then changed by 0.0% to $8.8 million in 2021, then changed by 0.0% to $8.8 million in 2022, then changed by 0.0% to $8.8 million in 2023.
• The last three Non-Current Deffered Revenue figures came in at $8.8 million (Q2 2023), $8.8 million (Q1 2023), and $8.8 million (Q4 2022), per Business Quant data.